K Papp, C Paul, C E Kleyn, Y-H Huang, T-F Tsai, C Schuster, C El Baou, A Toth, E Riedl, U Mrowietz
Issues - Aprile 2022
K Papp, C Paul, C E Kleyn, Y-H Huang, T-F Tsai, C Schuster, C El Baou, A Toth, E Riedl, U Mrowietz
A Blauvelt, N Shi, M Murage, T Ridenour, C Lew, N Somani, B Zhu, N Zimmerman, S Kern, R Burge
Long-term treatment patterns among patients with psoriasis treated with ixekizumab or adalimumab: A real-world study
J Drugs Dermatol. 2022 Apr 1;21(4):399-407A Blauvelt, T-F Tsai, R G Langley, M Miller, Y-K Shen, Y Y, Y-W Yang, K A Papp, L Puig
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
J Am Acad Dermatol. 2022 Apr;86(4):827-834C Ryan, L Guenther, P Foley, J Weisman, R T Burge, G Gallo, K See, M McKean-Matthews, C C Bertram, J F Merola
Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial
J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e277-e279J F Merola, H Tian, D Patil, C Richardson, A Scott, Y-H Chen, N Kim, P Hur, A W Armstrong
Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States
J Am Acad Dermatol. 2022 Apr;86(4):748-757R Oliver, J G Krueger, S Glatt, P Vajjah, C Mistry, M Page, H Edwards, S Garcet, X Li, B Dizier, A Maroof, M Watling, A El Baghdady, D Baeten, L Ionescu, S Shaw
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study
Br J Dermatol. 2022 Apr;186(4):652-663J Liu, A Thatiparthi, A Martin, J J Wu
Association between psoriasis and thyroid dysfunction among US adults in the 2009-2014 National Health and Nutrition Examination Survey
J Am Acad Dermatol. 2022 Apr;86(4):897-899J J Yang, K A Nguyen, M W Fleischman, O Aly, K Cheng
Psoriasis in liver disease: Associations beyond nonalcoholic fatty liver disease
J Am Acad Dermatol. 2022 Apr;86(4):883-885A Cristaudo, D Graceffa, F Pimpinelli, F Sperati, G Spoletini, C Bonifati, R Pellini, V Lora, M Pontone, O Di Bella, D Bracco, A Morrone
Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs
J Eur Acad Dermatol Venereol. 2022 Apr;36(4):e266-e268K Ikumi, K Torii, Y Sagawa, Y Kanayama, A Nakada, H Nishihara, A Morita
Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients
J Dermatol. 2022 Apr;49(4):e125-e126K A Papp, M J Gooderham, L E Albrecht, M-A Raymond, C W Lynde
Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting
Br J Dermatol. 2022 Apr;186(4):726-728John S Barbieri, Rinad S Beidas, George C Gondo, Jessica Fishman, Nathaniel J Williams, April W Armstrong, Alexis R Ogdie, Nehal Mehta, Joel M Gelfand
Analysis of specialist and patient perspectives on strategies to improve cardiovascular disease prevention among persons with psoriatic disease
JAMA Dermatol. 2022 Mar 1;158(3):252-259Alessandra Michelucci, Flavia Manzo Margiotta, Salvatore Panduri, Annalisa Tonini, Marco Romanelli, Riccardo Morganti, Agata Janowska, Valentina Dini
A real-life experience as a proof of guselkumab effectiveness and safety in patients with moderate to severe psoriasis
Dermatol Ther. 2022 Apr;35(4):e15339Alison Havelin, Philip Hampton
Telemedicine and e-health in the management of psoriasis: improving patient outcomes – A narrative review
Psoriasis (Auckl). 2022 Mar 16;12:15-24Åshild Ø Solvin, Konika Chawla, Lene C Olsen, Siv Anita Hegre, Kjersti Danielsen, Marita Jenssen, Anne-Sofie Furberg, Marit Saunes, Kristian Hveem, Pål Saetrom, Mari Løset
MicroRNA profiling of psoriatic skin identifies 11 miRNAs associated with disease severity
Exp Dermatol. 2022 Apr;31(4):535-547Noha Mohammed Dawoud, Maha Bedair El Badawy, Hala Subhi Al Eid, Moataz M Abdel Fattah
Risankizumab effectiveness and safety in psoriasis patients who failed other biologics: Real-life case series
Indian J Dermatol Venereol Leprol. Mar-Apr 2022;88(2):235-240Maartje R van Acht, Juul MPA van den Reek, Elke MGJ de Jong, Marieke MB Seyger